Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All

The Lead

British Man Shedded Mutated Polio Strain for 28 Years

September 3, 2015 | by Ryan Bushey, Associate Editor | News | Comments

Researchers performing the study found the mutated virus after analyzing more than 100 stool samples from the patient. Read more...

View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Scientists Find Neuron Responsible for Alcoholism Craving

September 3, 2015 10:37 am | by Seth Augenstein, Digital Reporter | News | Comments

A particular neuron in the brain reaches out for the next drink – potentially functioning as a seat of alcoholism and other addictions, according to research by Texas A&M scientists. Alcohol alters neurons in the dorsomedial striatum, a part of the brain singled out to be important in goal-driven behavior, according to the study,published in the Journal of Neuroscience. Read more...


Hookah and E-Cigs Viewed as Safe by the Young

September 3, 2015 10:10 am | by Greg Watry, Digital Reporter | News | Comments

Researchers found young adults under 25 are more likely to rate hookah and e-cigarettes as safer. Read more...


Drug for Fungal Infections in Lung Transplant Recipients Increases Risk for Cancer, Death

September 3, 2015 9:54 am | by University of California, San Francisco | News | Comments

Voriconazole, a prescription drug commonly used to treat fungal infections in lung transplant recipients, significantly increases the risk for skin cancer and even death, according to a new study by UC San Francisco researchers. The team recommends physicians consider patient-specific factors that could modify the drug’s risks and benefits, when providing care. Read more...


Researchers Report Long-Term Remissions in First Personalized Cell Therapy Trial

September 3, 2015 9:50 am | by University of Pennsylvania School of Medicine | News | Comments

Eight of 14 patients in the first trial of the University of Pennsylvania's personalized cellular therapy for chronic lymphocytic leukemia (CLL) responded to the therapy, with some complete remissions continuing past four and a half years. Read more...


Legionnaires' Outbreaks Not Unusual in Summer & Early Fall

September 3, 2015 9:30 am | by Lindsay Tanner, AP Medical Writer | News | Comments

Legionnaires' disease has been reported in a handful of states this summer, leading to 19 deaths and more than 100 illnesses. The unrelated cases are part of a typical pattern seen with a disease that tends to appear in warm weather and is mostly dangerous for people who already are sick or weakened. Read more...


Scientists Move Closer to Curing Eye Disorder

September 3, 2015 8:15 am | by University of Manchester | News | Comments

Scientists have successfully restored the site of laboratory mice suffering from a common cause of blindness in people. Read more...


Ballooning Platelets and the Future of Anti-Thrombotic Drugs

September 3, 2015 8:00 am | by University of Bristol | News | Comments

Platelets play a central role in stopping bleeding (haemostasis) and causing blockages in arteries (arterial thrombosis), particularly in coronary artery disease. Read more...


Brain Disease Similar to Mad Cow is First to be Linked to Rogue Proteins in 50 Years

September 2, 2015 3:22 pm | by Seth Augenstein, Digital Reporter | News | Comments

Multiple System Atrophy, a brain disorder is caused by a newly-= discovered prion linking it to incurable diseases like mad cow and Creutzfeldt-Jakob disease, according to new research. Read more...


FDA Approves Tesaro’s Rolapitant (Varubi) for Chemo-Induced Nausea

September 2, 2015 12:33 pm | by Stephanie Guzowski, Editor | News | Comments

The U.S. Food and Drug Administration approved Tesaro’s treatment for chemotherapy-induced nausea and vomiting (CINV) in adults, the company announced Wednesday.The drug, rolapitant, which will be marketed as Varubi, is Tesaro’s first product to win FDA approval. Read more...


Gilead's Investigational Fixed-Dose F/TAF Combination Meets Primary Objective in Phase 3

September 2, 2015 11:22 am | News | Comments

Gilead Sciences, Inc. today announced that a Phase 3 study evaluating its investigational fixed-dose combination of emtricitabine and tenofovir alafenamide (200/10 mg and 200/25 mg) (F/TAF) for the treatment of HIV-1 infection met its primary objective. Read more... 


Young at Heart? Not Most Americans, Government Report Says

September 2, 2015 11:16 am | by Mike Stobbe, AP Medical Writer | News | Comments

Your heart might be older than you are. A new government report suggests age is just a number - and perhaps not a very telling one when it comes to your risk of heart attack or stroke. Read more...


Sanofi, Regeneron: New Phase 3 Positive Data for Alirocumab

September 2, 2015 11:10 am | News | Comments

Sanofi and Regeneron Pharmaceuticals, Inc. announced today that in a new pooled analysis of heterozygous familial hypercholesterolemia (HeFH) patients included in the ODYSSEY clinical trial program, Praluent (alirocumab) significantly reduced bad cholesterol, known as low-density lipoprotein cholesterol (LDL-C).  Read more..


Flu Study, On Hold, Yields New Vaccine Technology

September 2, 2015 11:05 am | by University of Wisconsin-Madison | News | Comments

Vaccines to protect against an avian influenza pandemic as well as seasonal flu may be mass produced more quickly and efficiently using technology described today by researchers at the University of Wisconsin-Madison in the journal Nature Communications. Read more...


FDA Issues Warning Letters to Powdered Caffeine Distributors

September 2, 2015 10:57 am | by Ann Sanner, Associated Press | News | Comments

The Food and Drug Administration has issued warning letters to five distributors of pure powdered caffeine, saying the products put consumers at risk. Read more...


Valeant, AstraZeneca to Partner on Brodalumab

September 2, 2015 8:05 am | News | Comments

Brodalumab is an IL-17 receptor monoclonal antibody in development for patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. Read more...



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.